PGS,
I always appreciate your comments on the board and I respect your scientific knowledge and opinion.
But you make the choices much too binary, i.e. it is not simply a question of a "trading vehicle" vs. fundamental scientific analysis. There are many other factors such as management competency and reliability, whether the trials are the right ones to run, size of the market, competition, cash position, patent position, etc.
So when people come to the board asking for an opinion "because of this or that biological reason," that may be just one factor out of a myriad of factors that a particular investor is considering in his/her evaluation. If the particular investor doesn't necessarily follow the advice relating to the drug or its trials, that doesn't necessarily mean that they consider the stock a "trading vehicle."
Bladerunner